An aflibercept biosimilar demonstrated positive results in the treatment of wet age-related macular degeneration in a phase 3 study, according to a press release from Sandoz.
The Mylight phase 3 confirmatory efficacy and safety study investigated the biosimilar in comparison to the reference biologic Eylea (aflibercept, Regeneron), which is indicated for neovascular AMD, diabetic macular edema, macular edema secondary to retinal vein occlusion and other neovascular retinal diseases.
The study met its primary efficacy endpoint of therapeutic equivalence in mean change of best corrected visual